Febuxostat is a urate-lowering drug, indicated for the treatment of hyperuricemia and gout. During the process development of febuxostat, nine process related impurities were observed at a level of 0.1-0.15 area percent. Synthesis and characterization of these impurities and investigation of their formation is described.